Company Operations During COVID-19 Imposed State of Emergency
Our sincere condolences to victims of COVID-19, and hopes for the quick recovery of those who have been infected. We also offer sincere gratitude towards healthcare professionals on the forefront of the fight against the virus, and everyone helping to support the community infrastructure.
Responding to the Japanese government’s May 7 announcement to expand the COVID-19-related state of emergency to Aichi and Fukuoka prefectures, PHC Holdings Corporation (headquarters: Tokyo, Japan) will be closing company sites in the applicable areas from May 12, prioritizing the safety of customers and employees. During the closure, PHC Group employees at the sites listed below will continue business operations by working from home, except in special cases where they perform essential duties that cannot be performed remotely, and will respond to customer inquiries by e-mail, phone calls, etc.
· Site closures
|・Biomedical Business Unit
Chubu Sales Office/Pharmacy System Sales Office/Delicart Sales Office
(Address: Nagoya Panasonic Building 6F, 1-23-30 Izumi, Higashi-ku, Nagoya City, Aichi)
Kyushu Sales Office/Pharmacy System Sales Office
(Address: Riverain Center Building 11F, 3-1 Shimokawabata-machi, Hakata-ku, Fukuoka City, Fukuoka)
・Medical Information Systems Business Unit
Kyushu Sales Office
(address as above)
Details of additional upcoming measures at the above sites will be announced respectively by each business division in charge, where appropriate. Resuming of operations at the sites will be considered depending on national and local government policies and the status of the COVID-19. We appreciate your understanding and apologize for any inconvenience or disruption that you may experience.
The health and safety of our customers, patients, employees and their families are most important to the PHC Group and we will continue to further strengthen measures to prevent internal and external spread of the infection, while working to ensure stable supply for customers and patients who rely on our products and services.